dNANOSIS, a Rapid and Sensitive RNA Detection for Point-of-Care Screening of Infectious Diseases
Inventor (s): Jinglin Fu
Date Awarded: March 2021
Summary:
dNANOSIS is a nucleic-acid assay capable of performing rapid and reliable screening for confirming viral infection in less than 1 hour. dNANOSIS is developed based on a technology of DNA-mediated proximity-assembly circuit (DPAC), which can directly detect viral-specific nucleic acid sequences with a triggered biochemical reaction to produce fluorescence/color signal. dNANOSIS can directly handle blood and swab sample with a simple procedure and a rapid viral RNA read-out for point-of-care use by transplant surgeons and health professionals. The unique features and value proposition include (1) a rapid assay within 1 hour, (2) a reliable and confirmative assay for detecting viral RNA, (3) a simple paper trip for signal read-out, (4) affordable cost. dNANOSIS will improve health outcomes by improving utilization of viremic organs and reducing healthcare costs by initiating early treatment. Further, the product is adaptable, and can be easily customized for mass screening surveillance for emerging infectious diseases and variants, such as the current COVID-19 pandemic.
Market Applications:
- HCV screening for organ transplant
- COVID-19 and variants screening
- Other emerging pandemic/epidemic diseases
